BLLN.US BillionToOne, Inc. Class A Common Stock
- Market cap
- USD 5.02B
- P/E
- 114.3x
- P/B
- 9.35x
- ROE
- 10.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BLLN.US undervalued?
Graham numberThe Graham number of BillionToOne, Inc. Class A Common Stock cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BillionToOne, Inc. Class A Common Stock fundamental analysis
No fundamental analysis for BillionToOne, Inc. Class A Common Stock yet.
BillionToOne, Inc. Class A Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BillionToOne, Inc. Class A Common Stock
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy t…
Full company profileBillionToOne, Inc. Class A Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BillionToOne, Inc. Class A Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 71.7M | 153M | 305M | 454M |
| Gross Profit | 17.3M | 80.9M | 208M | 324M |
| Operating Income | -69.5M | -47.1M | 16.0M | 45.8M |
| EBITDA | -72.9M | -27.5M | 19.8M | 66.4M |
| Net Income | -82.7M | -41.6M | 7.45M | 57.9M |
| EPS | -1.85 | -4.12 | 0.35 | 1.08 |
| Balance Sheet | ||||
| Total Assets | 192M | 302M | 633M | 760M |
| Total Liabilities | 161M | 134M | 153M | 194M |
| Shareholders' Equity | 30.5M | 168M | 480M | 567M |
| Cash & Short-term Investments | 97.3M | 191M | 496M | 562M |
| Total Debt | 146M | 109M | 109M | 140M |
| Cash Flow | ||||
| Operating Cash Flow | -53.7M | -41.4M | 24.6M | 49.5M |
| Capital Expenditure | 6.17M | 5.40M | 8.88M | 16.6M |
| Free Cash Flow | -59.8M | -46.8M | 15.7M | 32.9M |
| Ratios | ||||
| ROE | -271.3% | -24.8% | 1.6% | 10.2% |
| ROA | -43.1% | -13.8% | 1.2% | 7.6% |
| Net Profit Margin | -115.3% | -27.2% | 2.4% | 12.7% |
| Debt to Equity | 4.80x | 0.65x | 0.23x | 0.25x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
BillionToOne, Inc. Class A Common Stock dividends
BillionToOne, Inc. Class A Common Stock has not paid dividends in the last 3 fiscal years.
Who owns BillionToOne, Inc. Class A Common Stock
- Insiders 28.28%
- Institutions 47.90%
- Public & others 23.83%
- Shares outstanding 43.3M
- Free float 29.3M
Top funds holding BLLN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 728K | 1.59% | +0.30% | Sep 2026 |
| Invesco Discovery A | 585K | 1.28% | +10.04% | Sep 2026 |
| Vanguard Small Cap Index | 528K | 1.15% | +0.79% | Sep 2026 |
| T. Rowe Price Health Sciences | 309K | 0.67% | 0.00% | Sep 2026 |
| T. Rowe Price Small-Cap Stock | 306K | 0.67% | -0.57% | Sep 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 294K | 0.64% | +95.90% | Sep 2026 |
| Baron Discovery Institutional | 287K | 0.63% | 0.00% | Sep 2026 |
| FullerThaler Behavioral Sm-Cp Gr R6 | 275K | 0.60% | 0.00% | Jun 2026 |
| Oberweis Small-Cap Opportunities | 264K | 0.58% | 0.00% | Jun 2026 |
| Adams Street Private Eq Navigator LLC M | 247K | 0.54% | 0.00% | Jun 2026 |
| Edinburgh Worldwide Ord | 240K | 0.52% | 0.00% | Jun 2026 |
| Baillie Gifford Positive Change B Acc | 183K | 0.40% | +194.19% | Sep 2026 |
| Wasatch Small Cap Growth Investor | 167K | 0.37% | -18.18% | Sep 2026 |
| T. Rowe Price New Horizons | 167K | 0.36% | 0.00% | Sep 2026 |
| Invesco Main Street Small Cap R6 | 166K | 0.36% | 0.00% | Sep 2026 |
| T. Rowe Price Instl Small-Cap Stock | 165K | 0.36% | -2.49% | Sep 2026 |
| Columbia Small Cap Growth Inst | 149K | 0.32% | +94.59% | Sep 2026 |
| Alger Small Cap Focus I | 144K | 0.31% | 0.00% | Aug 2026 |
| JPMorgan Small Cap Growth A | 132K | 0.29% | -0.61% | Sep 2026 |
| Franklin Small Cap Growth Adv | 129K | 0.28% | +18.13% | Sep 2026 |
Top institutions holding BLLN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Adams Street Partners LLC | 1.71M | 3.63% | 0.00% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 1.01M | 2.14% | +36.99% | Jun 2026 |
| Baillie Gifford & Co Limited. | 901K | 1.91% | -28.46% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 841K | 1.78% | +456.15% | Jun 2026 |
| Amvescap Plc. | 836K | 1.77% | +105.56% | Jun 2026 |
| Vanguard Capital Management, LLC | 799K | 1.69% | +338.15% | Jun 2026 |
| Neuberger Berman Group LLC | 764K | 1.62% | +7.76% | Jun 2026 |
| BAMCO Inc | 742K | 1.57% | +0.08% | Jun 2026 |
| Wasatch Advisors LP | 518K | 1.10% | +40.16% | Jun 2026 |
| Millennium Management LLC | 425K | 0.90% | 0.00% | Jun 2026 |
| Fuller & Thaler Asset Management Inc | 419K | 0.89% | 0.00% | Jun 2026 |
| Emerald Advisers, LLC | 376K | 0.80% | +56.89% | Jun 2026 |
| Next Century Growth Investors LLC | 364K | 0.77% | +302.44% | Jun 2026 |
| UBS Group AG | 344K | 0.73% | +183.12% | Jun 2026 |
| JPMorgan Chase & Co | 340K | 0.72% | +20.21% | Jun 2026 |
| Ameriprise Financial Inc | 321K | 0.68% | +45.71% | Jun 2026 |
| Oberweis Asset Management Inc | 299K | 0.63% | 0.00% | Jun 2026 |
| Wells Fargo & Co | 272K | 0.58% | +24,408.48% | Jun 2026 |
| AllianceBernstein L.P. | 262K | 0.56% | +17.40% | Jun 2026 |
| NAPEAN TRADING AND INVESTMENT CO (SINGAPORE) PTE Ltd. | 233K | 0.49% | 0.00% | Jun 2026 |
BillionToOne, Inc. Class A Common Stock company profile
- Company name
- BillionToOne, Inc. Class A Common Stock
- Ticker
- BLLN.US
- Exchange
- USA Stocks
- Listed since
- Nov 6, 2025
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 713
- Fiscal year end
- December
- Address
- 1035 O?Brien Drive, Menlo Park, CA, United States, 94025
- Phone
- 650 460 2551
- Website
- billiontoone.com
About BillionToOne, Inc. Class A Common Stock
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.
BillionToOne, Inc. Class A Common Stock management
10- Dr. Oguzhan Atay Ph.D.Co-Founder, Chairman & CEO · born 1989
- Dr. David Tsao Ph.D.Co-Founder, President, CTO & Director · born 1990
- Mr. John D. Lister J.D.Chief Administrative Officer · born 1975
- Mr. Ross Taylor Jr., M.B.A.Chief Financial Officer · born 1963
- Ms. Jean HaydenVP of Business Operations & Chief of Staff
- Mr. Thomas P. Lynch J.D.Chief Compliance Officer, General Counsel & Secretary · born 1967
- Ms. Nancy JohnsonSenior Vice President of Sales & Commercial Operations · born 1964
- Ms. Jaclyn EngVice President of Marketing
- Mr. Vaghar HaghiriSenior Director of People Operations
- Ms. Shan Riku Sakakibara M.B.A.Chief Product Officer · born 1984